- Home
- SYRE
as of 12-05-2025 3:46pm EST
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.1B | IPO Year: | 2016 |
| Target Price: | $55.50 | AVG Volume (30 days): | 652.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.91 - $34.54 | Next Earning Date: | 11-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered SYRE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Spyre Therapeutics Inc. (SYRE)
Chief Executive Officer
Avg Cost/Share
$29.28
Shares
15,000
Total Value
$435,355.50
Owned After
690,912
Chief Executive Officer
Avg Cost/Share
$23.40
Shares
45,000
Total Value
$1,049,777.85
Owned After
690,912
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Turtle Cameron | SYRE | Chief Executive Officer | Dec 1, 2025 | Sell | $29.28 | 15,000 | $435,355.50 | 690,912 | |
| Turtle Cameron | SYRE | Chief Executive Officer | Nov 3, 2025 | Sell | $23.40 | 45,000 | $1,049,777.85 | 690,912 |
Compare SYRE vs Leading Stocks
See how SYRE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SYRE Spyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.